Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation

Vista senzilla d'ítem
dc.contributor.authorOrtiz-Maldonado Gibson, Valentín
dc.contributor.authorFrigola, Gerard
dc.contributor.authorEspañol Rego, Marta
dc.contributor.authorBalagué, Olga
dc.contributor.authorMartínez Cibrian, Nuria
dc.contributor.authorMagnano, Laura
dc.contributor.authorGiné Soca, Eva
dc.contributor.authorPascal i Capdevila, Mariona
dc.contributor.authorCorrea, Juan G.
dc.contributor.authorMartínez Roca, Alexandra
dc.contributor.authorCid Vidal, Joan
dc.contributor.authorLozano Molero, Miguel
dc.contributor.authorVillamor i Casas, Neus
dc.contributor.authorBenítez-Ribas, Daniel
dc.contributor.authorEsteve Comas, Jordi
dc.contributor.authorLópez Guillermo, Armando
dc.contributor.authorCampo Güerri, Elias
dc.contributor.authorUrbano Ispizua, Álvaro
dc.contributor.authorJuan, Manel
dc.contributor.authorDelgado, Julio (Delgado González)
dc.date.accessioned2023-05-08T09:43:51Z
dc.date.available2023-05-08T09:43:51Z
dc.date.issued2022-01-31
dc.date.updated2023-05-02T07:59:08Z
dc.description.abstractCART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high risk CLL or RT
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina9298925
dc.identifier.issn2234-943X
dc.identifier.pmid35174095
dc.identifier.urihttps://hdl.handle.net/2445/197660
dc.language.isoeng
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fonc.2022.828471
dc.relation.ispartofFrontiers In Oncology, 2022, vol.12, num. 828471
dc.relation.urihttps://doi.org/10.3389/fonc.2022.828471
dc.rightscc by (c) Ortiz Maldonado, Valentín et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationLeucèmia limfocítica crònica
dc.subject.classificationTeràpia cel·lular
dc.subject.otherChronic lymphocytic leukemia
dc.subject.otherCellular therapy
dc.titleResults of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia_FrontiersInOncology.pdf
Mida:
5.58 MB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)